Wolverine Trading
CLVS

Wolverine Trading’s Clovis Oncology, Inc. CLVS Stock Holding History

Wolverine Trading’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49,400
Closed -$84K – 5641
2022
Q2 		$84K Buy
49,400
+35,400
+253% +$52.2K ﹤0.01% 3895
2022
Q1 		$23K Buy
14,000
+1,000
+8% +$1.96K ﹤0.01% 5230
2021
Q4 		$37K Sell
13,000
-27,300
-68% -$101K ﹤0.01% 5412
2021
Q3 		$182K Sell
40,300
-27,800
-41% -$134K ﹤0.01% 5417
2021
Q2 		$398K Sell
68,100
-6,200
-8% -$36.3K ﹤0.01% 4033
2021
Q1 		$504K Buy
74,300
+7,300
+11% +$48.9K ﹤0.01% 3687
2020
Q4 		$330K Buy
67,000
+23,700
+55% +$120K ﹤0.01% 3651
2020
Q3 		$257K Sell
43,300
-16,000
-27% -$95.7K ﹤0.01% 3584
2020
Q2 		$417K Buy
+59,300
New +$449K ﹤0.01% 2942
2019
Q4 		– Sell
-31,900
Closed -$128K – 5406
2019
Q3 		$128K Buy
31,900
+7,400
+30% +$59.9K ﹤0.01% 3774
2019
Q2 		$364K Sell
24,500
-14,500
-37% -$262K ﹤0.01% 3061
2019
Q1 		$968K Sell
39,000
-8,100
-17% -$203K ﹤0.01% 2102
2018
Q4 		$846K Buy
47,100
+18,200
+63% +$372K ﹤0.01% 2121
2018
Q3 		$849K Sell
28,900
-10,500
-27% -$407K ﹤0.01% 2539
2018
Q2 		$2.08M Hold
39,400
– – 0.01% 1555
2018
Q1 		$2.08M Sell
39,400
-58,300
-60% -$3.4M 0.01% 1555
2017
Q4 		$6.64M Sell
97,700
-17,300
-15% -$1.21M 0.02% 698
2017
Q3 		$9.48M Sell
115,000
-34,000
-23% -$2.7M 0.04% 445
2017
Q2 		$13.7M Buy
149,000
+47,200
+46% +$2.89M 0.06% 287
2017
Q1 		$6.39M Buy
+101,800
New +$6.19M 0.04% 537
2016
Q4 		– Sell
-30,100
Closed -$1.04M – 5375
2016
Q3 		$1.04M Sell
30,100
-6,000
-17% -$129K ﹤0.01% 1816
2016
Q2 		$544K Buy
+36,100
New +$528K ﹤0.01% 2152

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wolverine Trading's CLVS Position: Q3 2022 in Review

Wolverine Trading sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 45,133 shares — an estimated $77K sold.

Wolverine Trading first reported a position in CLVS in Q2 2016 and held it in 17 quarters. The position peaked at $6.65M in Q2 2017. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Wolverine Trading reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Wolverine Trading sold 45,133 Clovis Oncology, Inc. shares in Q3 2022, an estimated $77K.
  • Wolverine Trading first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 17 quarters.
  • Wolverine Trading's Clovis Oncology, Inc. position peaked at $6.65M in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.